文献速递腹部CT

双能CT细胞外容积分数预测局部晚期胃癌新辅助免疫化疗后肿瘤退缩分级

Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction.
PubMed 文献 · Eur Radiol · 2024-07-09

该回顾性研究纳入88例接受术前免疫化疗的局部晚期胃腺癌患者,用双能CT延迟期碘图计算细胞外容积分数(ECV)预测病理完全缓解(pCR)。21例(23.9%)达pCR,ECV可独立预测pCR(平均OR 0.911,95%CI 0.798-0.994),联合ECV、肿瘤面积和IDAV的模型训练集与验证集平均AUC分别为0.780和0.766。

要点

  • 双能CT延迟期ECV分数与局部晚期胃癌术前免疫化疗后pCR相关,平均OR 0.911(95%CI 0.798-0.994)。
  • 联合ECV、肿瘤面积和IDAV的加权逻辑回归模型预测pCR,训练集平均AUC 0.780、验证集0.766。
  • 单变量分析显示ECV在pCR与非pCR组间差异有统计学意义(平均P值0.021)。

核心结论

  • 双能CT延迟期ECV分数是局部晚期胃癌患者接受术前免疫化疗后肿瘤退缩分级的有价值预测指标,可无创识别潜在治疗获益者。

研究设计与样本

  • 回顾性分析2019年8月至2023年3月在本机构接受术前免疫化疗的局部晚期胃腺癌患者88例(平均年龄60.8±11.1岁,男63例),按TRG分为pCR组与非pCR组,采用双能CT延迟期碘图测定ECV,并用三期增强碘图分析肿瘤碘密度和标准化碘比值。

诊断标准与关键数值

  • 以病理TRG为参考标准,pCR 21例(23.9%);单变量分析中ECV区分pCR与非pCR组的平均P值为0.021;逻辑回归模型中ECV独立预测pCR的平均OR为0.911(95%CI 0.798-0.994);含ECV、肿瘤面积和IDAV的模型预测pCR的训练集平均AUC为0.780(0.770-0.791),验证集为0.766(0.731-0.800)。

临床应用与阅片要点

  • 作者认为双能CT延迟期ECV分数可作为局部晚期胃癌术前免疫化疗后pCR的可靠预测指标,为识别潜在治疗获益者提供无创工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study examines the effectiveness of dual-energy CT (DECT) delayed-phase extracellular volume (ECV) fraction in predicting tumor regression grade (TRG) in far-advanced gastric cancer (FAGC) patients receiving preoperative immuno-chemotherapy.

MATERIALS AND METHODS: A retrospective analysis was performed on far-advanced gastric adenocarcinoma patients treated with preoperative immuno-chemotherapy at our institution from August 2019 to March 2023. Patients were categorized based on their TRG into pathological complete response (pCR) and non-pCR groups. ECV was determined using the delayed-phase iodine maps. In addition, tumor iodine densities and standardized iodine ratios were meticulously analyzed using the triple-phase enhanced iodine maps. Univariate analysis with five-fold cross-validation and Spearman correlation determined DECT parameters and clinical indicators association with pCR. The predictive accuracy of these parameters for pCR was evaluated using a weighted logistic regression model with five-fold cross-validation.

RESULTS: Of the 88 patients enrolled (mean age 60.8 ± 11.1 years, 63 males), 21 (23.9%) achieved pCR. Univariate analysis indicated ECV's significant role in differentiating between pCR and non-pCR groups (average p value = 0.021). In the logistic regression model, ECV independently predicted pCR with an average odds ratio of 0.911 (95% confidence interval, 0.798-0.994). The model, incorporating ECV, tumor area, and IDAV (the relative change rate of iodine density from venous phase to arterial phase), showed an average area under curves (AUCs) of 0.780 (0.770-0.791) and 0.766 (0.731-0.800) for the training and validation sets, respectively, in predicting pCR.

CONCLUSION: DECT-derived ECV fraction is a valuable predictor of TRG in FAGC patients undergoing preoperative immuno-chemotherapy.

CLINICAL RELEVANCE STATEMENT: This study demonstrates that DECT-derived extracellular volume fraction is a reliable predictor for pathological complete response in far-advanced gastric cancer patients receiving preoperative immuno-chemotherapy, offering a noninvasive tool for identifying potential treatment beneficiaries.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Jiang J, Yan C, et al. Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction. Eur Radiol. 2024. PMID: 38981889. doi:10.1007/s00330-024-10737-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。